Source comparison
BPC-157 Gut Health Protocol Dosage Timing: Clinical Context vs Research Use
Dose per administration 250–500mcg subcutaneous 100–1000mcg range reported 250–500mcg supported by rodent-to-human allometric scaling; doses above 500mcg show no proportional benefit in published trials Frequency Twice daily (morning/evening) Once daily or thr
This comparison does not assign a generated winner or score.
- Dose per administration
- 250–500mcg subcutaneous
- 100–1000mcg range reported
- 250–500mcg supported by rodent-to-human allometric scaling; doses above 500mcg show no proportional benefit in published trials
- Frequency
- Twice daily (morning/evening)
- Once daily or three times daily
- Twice-daily aligns with mucosal repair cycles; once-daily reduces compliance burden but extends time to observable effects
- Timing relative to meals
- 30 minutes before meals
- Random timing or post-meal
- Pre-meal captures neutral pH window and maximizes mucosal contact before digestive motility
- Injection site
- Abdominal subcutaneous (2–3 inches from navel)
- Thigh, deltoid, or random sites
- Abdominal injection achieves higher local GI tissue concentration; systemic distribution occurs regardless
- Protocol duration
- 4–6 weeks minimum
- 2 weeks to 12+ weeks
- Mucosal healing markers (reduced inflammation, epithelial closure) typically require 4–6 weeks; shorter durations may show subjective improvement without measurable tissue change
- Reconstitution volume
- 2–3mL bacteriostatic water per 5mg vial
- 1–5mL range
- 2mL yields 250mcg per 0.1mL, simplifying measurement; more dilute solutions reduce injection discomfort but require larger volumes